General Electric’s Pacira BioSciences PCRX Stock Holding History

General Electric’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-24,409	Closed	-$1.4M	–	216
2013 Q4	$1.4M	Buy	+24,409	New	+$1.28M	0.01%	187
2013 Q3	–	Sell	-32,096	Closed	-$931K	–	219
2013 Q2	$931K	Buy	+32,096	New	+$928K	﹤0.01%	202

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return

General Electric's PCRX Position: Q1 2014 in Review

General Electric sold out of Pacira BioSciences (PCRX) in Q1 2014, closing a stake of 24,409 shares — an estimated $1.4M sold.

General Electric first reported a position in PCRX in Q2 2013 and held it in 2 quarters. The position peaked at $1.4M in Q4 2013. 160 funds tracked by Wall St. Rank hold PCRX as of Q1 2014.

General Electric reported no remaining Pacira BioSciences position as of Q1 2014 after selling out during the quarter.
General Electric sold 24,409 Pacira BioSciences shares in Q1 2014, an estimated $1.4M.
General Electric first reported a position in Pacira BioSciences in Q2 2013 and held it in 2 quarters.
General Electric's Pacira BioSciences position peaked at $1.4M in Q4 2013.
160 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2014.

Based on General Electric's 13F filing for Q1 2014, filed 13 May 2014.